Taiho’s CMO Dr Keer on positive REZILIENT3 data for zipalertinib combo
Taiho Oncology chief medical officer (CMO) Dr Harold Keer recently discussed with Srivani Venna the outcomes from the Phase III REZILIENT3…
Interviews
J&J’s Mark Graham on advancing nipocalimab as treatment for SLE
The slow march of clinical biomarkers to become surrogate endpoints
Biomarker-led trials to guide the future of precision psychiatry
Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials
From real to regulatory: why RWD needs trial-grade standards
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
FDA’s latest CGT guidance streamlines path for in vivo CAR-T development
